1. Home
  2. AKBA vs CTLP Comparison

AKBA vs CTLP Comparison

Compare AKBA & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$1.40

Market Cap

729.1M

Sector

Health Care

ML Signal

N/A

Logo Cantaloupe Inc.

CTLP

Cantaloupe Inc.

N/A

Current Price

$10.46

Market Cap

757.1M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
CTLP
Founded
2007
1992
Country
United States
United States
Employees
N/A
345
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
757.1M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AKBA
CTLP
Price
$1.40
$10.46
Analyst Decision
Strong Buy
Hold
Analyst Count
6
3
Target Price
$5.75
N/A
AVG Volume (30 Days)
3.2M
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
93.94
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.84
$16.11
Revenue Next Year
N/A
$14.37
P/E Ratio
N/A
$13.69
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$7.01
52 Week High
$4.08
$11.16

Technical Indicators

Market Signals
Indicator
AKBA
CTLP
Relative Strength Index (RSI) 56.02 52.17
Support Level $1.30 $9.82
Resistance Level $1.55 $10.77
Average True Range (ATR) 0.08 0.22
MACD 0.02 0.04
Stochastic Oscillator 68.92 63.36

Price Performance

Historical Comparison
AKBA
CTLP

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About CTLP Cantaloupe Inc.

Cantaloupe Inc is a technology leader powering self-service commerce by offering one integrated solution for payments processing, logistics, and back-office management. The group offers a comprehensive suite of solutions, including micro-payment processing, self-checkout kiosks, mobile ordering, connected point-of-sale (POS) systems, and enterprise cloud software. Its product and services portfolio consists of Card Readers, Self-Service Kiosks, Smart Coolers, Seed Pick Easy, Cantaloupe Go, Cheq, Smart Lock Connect, and Vine Digital Studio. The company derives revenue streams from subscriptions, transaction processing, and equipment sales.

Share on Social Networks: